Ben Munoz

A highly regarded scientist and medicinal chemist with extensive drug development experience, Ben has more than 20 years of experience in project management, managing cross-functional drug discovery project teams and strategic planning to his role at Vesalius. Prior to joining Vesalius, he spent eight years in senior leadership roles at Proteostasis Therapeutics, serving most recently as chief scientific officer. Prior, Ben was the director of medicinal chemistry at the Molecular Libraries Probe Productions Center Network (MLPCN) at the Broad Institute, a biomedical research institute affiliated with Harvard University and the Massachusetts Institute of Technology (MIT). At MLPCN, he was responsible for designing and implementing a phenotypic screening platform to identify active molecules within the Institute’s collection of small molecules. He also oversaw collaborations with Genzyme, Medicines for Malaria Venture (MMV), Gates Foundation and the World Health Organization (WHO). Ben began his career at SIBIA Neuroscience Inc., which was later acquired by Merck. Subsequently, he was director of medicinal chemistry at Merck Research Laboratories. In that role, he led key neuroscience programs delivering clinical candidates for Alzheimer’s disease (AD) and multiple sclerosis (MS).

Ben earned his PhD in organic chemistry from the University of Toronto and a master’s degree in chemistry from Brock University. He completed his postdoctoral training at the Scripps Research Institute.